CN101130498B - Method for extracting and purifying salvianolic acid A - Google Patents
Method for extracting and purifying salvianolic acid A Download PDFInfo
- Publication number
- CN101130498B CN101130498B CN200710070553A CN200710070553A CN101130498B CN 101130498 B CN101130498 B CN 101130498B CN 200710070553 A CN200710070553 A CN 200710070553A CN 200710070553 A CN200710070553 A CN 200710070553A CN 101130498 B CN101130498 B CN 101130498B
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- extracting
- extraction
- protein
- purifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 title claims abstract description 49
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000012141 concentrate Substances 0.000 claims abstract description 15
- 108010010803 Gelatin Proteins 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000008273 gelatin Substances 0.000 claims abstract description 13
- 229920000159 gelatin Polymers 0.000 claims abstract description 13
- 235000019322 gelatine Nutrition 0.000 claims abstract description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 13
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 11
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 11
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 9
- 238000000638 solvent extraction Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000001179 sorption measurement Methods 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 8
- 235000014103 egg white Nutrition 0.000 claims description 8
- 210000000969 egg white Anatomy 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 235000017276 Salvia Nutrition 0.000 claims description 4
- 230000006920 protein precipitation Effects 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims 7
- 235000005412 red sage Nutrition 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940022663 acetate Drugs 0.000 claims 1
- 229940043232 butyl acetate Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 20
- 244000132619 red sage Species 0.000 abstract description 20
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 5
- 238000004440 column chromatography Methods 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- CMVHOLZLFLESKY-UHFFFAOYSA-N Anisodine Natural products CN1C2CC(CC1C3OC23)C(=O)OC(O)(CO)c4ccccc4 CMVHOLZLFLESKY-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- JEJREKXHLFEVHN-QDXGGTILSA-N anisodine Chemical compound C1([C@](O)(CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 JEJREKXHLFEVHN-QDXGGTILSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000008886 xiangdan Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供一种丹酚酸A的提取纯化方法,以丹参饮片或粉末为原料,采用溶剂提取、浓缩得到丹参浓缩液,经蛋白质吸附、溶剂萃取法获取高纯度丹酚酸A。本发明利用明胶或者蛋清蛋白等沉淀丹酚酸A后,经丙酮水溶液溶解、解析,再经有机溶剂萃取获得高纯度的丹酚酸A。本发明方法最终提取物得率达0.3%以上,丹酚酸A的纯度达90%以上,避免了以往方法中的柱层析步骤。本发明方法设计合理,提取率高、纯度好、性能稳定、工艺简单、生产成本低,适合工业大生产。The invention provides a method for extracting and purifying salvianolic acid A, which uses danshen decoction pieces or powder as raw materials, uses solvent extraction and concentration to obtain salvia miltiorrhiza concentrate, and obtains high-purity salvianolic acid A through protein adsorption and solvent extraction. The present invention utilizes gelatin or egg white protein to precipitate salvianolic acid A, dissolves and analyzes in acetone aqueous solution, and then extracts with an organic solvent to obtain high-purity salvianolic acid A. The final extract yield of the method of the invention is over 0.3%, the purity of the salvianolic acid A is over 90%, and the column chromatography step in the conventional method is avoided. The method of the invention has the advantages of reasonable design, high extraction rate, good purity, stable performance, simple process and low production cost, and is suitable for large-scale industrial production.
Description
技术领域technical field
本发明属化合物制备,主要涉及一种丹酚酸A的提取纯化方法。The invention belongs to compound preparation, and mainly relates to a method for extracting and purifying salvianolic acid A.
背景技术Background technique
丹参是最常用的中药药材之一。用于治疗心绞痛、高血压、冠心病及中风等心脑血管疾病。以丹参饮片或者丹参粗提取物入药的中药制剂有很多,如复方丹参片、复方丹参滴丸、丹参注射液、香丹注射液等,另外也有利用从丹参中分离得到纯化合物或其盐类制成的制剂,如丹参素钠注射液、丹酚酸B针剂等。Salvia miltiorrhiza is one of the most commonly used Chinese medicinal herbs. For the treatment of cardiovascular and cerebrovascular diseases such as angina pectoris, hypertension, coronary heart disease and stroke. There are many traditional Chinese medicine preparations that use Danshen decoction pieces or crude extracts of Danshen as medicine, such as compound Danshen tablets, compound Danshen dripping pills, Danshen injection, Xiangdan injection, etc. In addition, there are also pure compounds or their salts prepared from Danshen Prepared preparations, such as Danshensu Sodium Injection, Salvianolic Acid B Injection, etc.
近年来,随着药理研究的深入,丹酚酸A的多种药理活性被发现。如甄永苏等发现丹酚酸A具有抗肿瘤活性;杜冠华等发现丹酚酸A对大鼠离体心肌缺血再灌注损伤具有明显的保护作用,对小鼠脑缺血再灌注引起的脑损伤有保护作用,对樟柳碱或冬莨菪碱引起的小鼠记忆获得障碍有明显的改善作用等;陶文(Tao Wen)等发现丹酚酸A对四氯化碳引起的大鼠肝损伤具有保护作用。李志刚等还开发了治疗心血管疾病的丹参丹酚酸A片剂及注射剂。In recent years, with the deepening of pharmacological research, various pharmacological activities of salvianolic acid A have been discovered. For example, Zhen Yongsu et al. found that salvianolic acid A has anti-tumor activity; Du Guanhua et al. found that salvianolic acid A has obvious protective effect on isolated myocardial ischemia-reperfusion injury in rats, and has a protective effect on brain injury caused by cerebral ischemia-reperfusion in mice. It has a protective effect on the memory acquisition disorder caused by anisodine or hyoscine in mice, etc.; Tao Wen (Tao Wen) found that salvianolic acid A has a protective effect on rat liver damage caused by carbon tetrachloride . Li Zhigang and others have also developed salvianolic acid A tablets and injections for the treatment of cardiovascular diseases.
中国专利CN1397276A,2002年公开了水或醇提、树脂层析,再经硅胶柱层析的纯化制备丹酚酸A的方法。中国专利CN1513848A,2003年公开了采用水温浸、离心、超滤、调酸、有机溶剂萃取再经反相柱层析制备丹酚酸A的方法。中国专利CN1830947A和中国专利CN1887849A,分别于2006年及2007年公开了采用水或者醇提取丹参药材,再通过树脂或凝胶或反相柱层析,最后调酸、有机溶剂萃取制备丹酚酸A的方法。Chinese patent CN1397276A disclosed in 2002 a method for preparing salvianolic acid A through water or alcohol extraction, resin chromatography, and purification by silica gel column chromatography. Chinese patent CN1513848A disclosed in 2003 a method for preparing salvianolic acid A by soaking in water, centrifuging, ultrafiltration, adjusting acid, extracting with organic solvent, and then reversed-phase column chromatography. Chinese patent CN1830947A and Chinese patent CN1887849A disclosed in 2006 and 2007, respectively, the use of water or alcohol to extract the medicinal material of Salvia miltiorrhiza, followed by resin or gel or reversed-phase column chromatography, and finally acid adjustment and organic solvent extraction to prepare salvianolic acid A Methods.
由于丹酚酸A在药材中含量很低,生产成本高。另外,柱层析在工业大生产上运用有一定的局限性,不能很好地满足工业上生产丹酚酸A制剂的需要。Since the content of salvianolic acid A in medicinal materials is very low, the production cost is high. In addition, the application of column chromatography in large-scale industrial production has certain limitations, and cannot well meet the needs of industrial production of salvianolic acid A preparations.
发明内容Contents of the invention
本发明针对现有技术存在的不足,提供一种丹酚酸A的提取纯化方法,本发明所采用的技术手段是:以丹参饮片或粉末为原料,采用溶剂提取、浓缩得到丹参浓缩液,经蛋白质吸附、溶剂萃取法获取高纯度丹酚酸A,具体通过以下步骤实现:Aiming at the deficiencies in the prior art, the present invention provides a method for extracting and purifying salvianolic acid A. The technical means used in the present invention are: taking Danshen decoction pieces or powder as raw materials, extracting and concentrating with solvents to obtain the concentrated liquid of Salvia miltiorrhiza. Protein adsorption and solvent extraction methods to obtain high-purity salvianolic acid A, specifically through the following steps:
1.获取丹参浓缩液:采用常规溶剂提取、浓缩法获取丹参浓缩液;1. Obtain Danshen Concentrate: Use conventional solvent extraction and concentration methods to obtain Salvia Concentrate;
将丹参饮片或粉末用水或者不同比例的乙醇水溶液,经过超声、温浸或加热回流提取,提取液经自然沉降、过滤或者离心除去不溶性杂质。常压或减压下浓缩,自然沉降、过滤或者离心除去不溶性杂质,制成丹参浓缩液;The Danshen decoction pieces or powder are extracted with water or different proportions of ethanol aqueous solution through ultrasonication, warm soaking or heating under reflux, and the extract is naturally settled, filtered or centrifuged to remove insoluble impurities. Concentrate under normal pressure or reduced pressure, naturally settle, filter or centrifuge to remove insoluble impurities, and make Danshen concentrate;
2.丹酚酸A纯化:用蛋白质吸附丹参浓缩液中丹酚酸A,再经丙酮解析、有机溶剂萃取,分离含丹酚酸A有机溶剂层;2. Purification of salvianolic acid A: use protein to adsorb salvianolic acid A in the concentrated solution of salvia miltiorrhiza, then analyze with acetone and extract with organic solvent to separate the organic solvent layer containing salvianolic acid A;
3.丹酚酸A浓缩干燥,获取纯化的丹酚酸A:采用减压浓缩或者常压浓缩,干燥采用真空干燥、喷雾干燥或冷冻干燥,获取纯化的丹酚酸A。3. Concentrate and dry salvianolic acid A to obtain purified salvianolic acid A: Concentrate under reduced pressure or normal pressure, and dry by vacuum drying, spray drying or freeze-drying to obtain purified salvianolic acid A.
步骤1中,温浸提取或者超声提取时优选丹参药材粉末,加热回流提取时优选丹参饮片;提取用溶剂为0~50%乙醇;丹参提取液浓缩至1 mL相当于0.5g~2g药材为宜。In step 1, Danshen herb powder is preferred for warm extraction or ultrasonic extraction, and Danshen decoction slices are preferred for heating and reflux extraction; the solvent for extraction is 0-50% ethanol; it is advisable to concentrate the Danshen extract to 1 mL, which is equivalent to 0.5g-2g of medicinal materials .
步骤2中,吸附所用的蛋白质选用明胶或蛋清,将明胶或蛋清溶于水中,制成一定浓度的蛋白水溶液;再将明胶或蛋清的蛋白水溶液加入到丹参浓缩液中,至不再产生沉淀,自然沉降、离心或者过滤获取丹酚酸A与蛋白质沉淀复合物;将复合物用丙酮水溶液溶解,自然沉降、离心或者过滤得到上清液,或直接加热溶解沉淀,常压或者减压下浓缩至无丙酮;In step 2, the protein used for adsorption is gelatin or egg white, and the gelatin or egg white is dissolved in water to make a certain concentration of protein aqueous solution; then the gelatin or egg white protein aqueous solution is added to the Danshen concentrated solution until no precipitation occurs. Natural sedimentation, centrifugation or filtration to obtain salvianolic acid A and protein precipitation complex; dissolve the complex with acetone aqueous solution, natural sedimentation, centrifugation or filtration to obtain supernatant, or directly heat to dissolve the precipitate, and concentrate to Acetone free;
步骤2中,当所选蛋白质为明胶时,其水溶液浓度为1%~20%,优选5%明胶水溶液;所选蛋白质为蛋清时,其水溶液浓度为1%~10%。In step 2, when the selected protein is gelatin, its aqueous solution concentration is 1%-20%, preferably 5% gelatin aqueous solution; when the selected protein is egg white, its aqueous solution concentration is 1%-10%.
步骤2中,明胶或蛋清的蛋白水溶液离心时转速为3000rpm以上。In step 2, the rotational speed of the aqueous protein solution of gelatin or egg white is more than 3000 rpm during centrifugation.
步骤2中丹酚酸A与蛋白质沉淀复合物所用的丙酮水溶液为10%~90%丙酮水溶液,优选为50%丙酮水溶液,离心时转速为8000rpm以上,直接加热溶解沉淀时,温度为40~100℃。In step 2, the acetone aqueous solution used for the compound of salvianolic acid A and protein precipitation is 10% to 90% acetone aqueous solution, preferably 50% acetone aqueous solution, and the rotation speed during centrifugation is above 8000 rpm, and when directly heating to dissolve the precipitate, the temperature is 40 to 100 ℃.
步骤2中所用有机溶剂为乙酸乙酯、乙酸丙酯、乙酸丁酯等乙酸酯类溶剂。The organic solvent used in step 2 is acetate solvents such as ethyl acetate, propyl acetate, butyl acetate.
本发明的丹酚酸A提取纯化方法,根据丹酚酸A具有能与蛋白质结合形成沉淀的性质,利用明胶或者蛋清蛋白等沉淀丹酚酸A后,沉淀再经丙酮水溶液溶解,将丹酚酸A从蛋白质沉淀中解析出来,经有机溶剂萃取获取高纯度的丹酚酸A,从而达到分离纯化丹酚酸A的目的。该方法最终提取物得率达0.3%以上,丹酚酸A的纯度达90%以上,避免了以往方法中的柱层析步骤。本发明方法设计合理,提取率高、纯度好、性能稳定、工艺简单、生产成本低,适合工业大生产。According to the extraction and purification method of salvianolic acid A of the present invention, salvianolic acid A has the property of being able to combine with protein to form a precipitate, after using gelatin or egg white protein to precipitate salvianolic acid A, the precipitate is then dissolved in acetone aqueous solution, and the salvianolic acid A is resolved from protein precipitation, and high-purity salvianolic acid A is obtained through organic solvent extraction, so as to achieve the purpose of separation and purification of salvianolic acid A. The final extract yield of the method is over 0.3%, the purity of the salvianolic acid A is over 90%, and the column chromatography step in the previous method is avoided. The method of the invention has the advantages of reasonable design, high extraction rate, good purity, stable performance, simple process and low production cost, and is suitable for large-scale industrial production.
附图说明Description of drawings
图1为丹酚酸A纯度检查色谱图。Fig. 1 is the chromatogram of checking the purity of salvianolic acid A.
具体实施方式Detailed ways
本发明结合附图和实施例作进一步的说明。The present invention will be further described in conjunction with drawings and embodiments.
实施例一Embodiment one
丹酚酸A的提取纯化方法,其工艺步骤为:The extraction and purification method of salvianolic acid A, its processing steps are:
1.取丹参药材,加入8倍量的水,煎煮回流3次,每次1小时,滤过,减压浓缩滤液至1ml相当于2g药材,滤过;1. Take the medicinal material of Danshen, add 8 times the amount of water, decoct and reflux 3 times, 1 hour each time, filter, concentrate the filtrate under reduced pressure to 1ml equivalent to 2g of medicinal material, and filter;
2.加入5%明胶水溶液至不再产生沉淀,4000rpm离心10min;往沉淀中加入相当于步骤2中浓缩液体积的50%的丙酮水溶液,60℃加热溶解沉淀;减压回收除去丙酮后,水溶液用等体积的乙酸乙酯萃取3次,合并有机相;2. Add 5% gelatin aqueous solution until no precipitation occurs, and centrifuge at 4000 rpm for 10 minutes; add acetone aqueous solution equivalent to 50% of the volume of the concentrated solution in step 2 to the precipitation, and heat at 60°C to dissolve the precipitation; after decompression recovery to remove acetone, the aqueous solution Extract 3 times with an equal volume of ethyl acetate, and combine the organic phases;
3.减压浓缩萃取液至浸膏状,冷冻干燥得淡黄色粉末,即为丹酚酸A。3. Concentrate the extract under reduced pressure to extract, and freeze-dry to obtain a light yellow powder, which is salvianolic acid A.
丹酚酸A纯度检查色谱图参见图1。See Figure 1 for the chromatogram of salvianolic acid A purity check.
实施例二Embodiment two
与实施例1基本相同,所不同的是提取溶剂为50%的乙醇水溶液。It is basically the same as Example 1, except that the extraction solvent is 50% aqueous ethanol.
实施例三Embodiment three
与实施例1基本相同,所不同的是步骤1中浓缩液浓缩至1ml相当于0.5 g药材。It is basically the same as in Example 1, except that the concentrated solution in step 1 is concentrated to 1 ml, which is equivalent to 0.5 g of medicinal materials.
实施例四Embodiment Four
与实施例1基本相同,所不同的是步骤2中所用明胶水溶液浓度为20%。It is basically the same as Example 1, except that the gelatin aqueous solution used in step 2 has a concentration of 20%.
实施例五Embodiment five
与实施例1基本相同,所不同的是步骤2中加入的丙酮水溶液浓度为80%丙酮水溶液。It is basically the same as Example 1, except that the concentration of the acetone aqueous solution added in step 2 is 80% acetone aqueous solution.
实施例六Embodiment six
与实施例1基本相同,所不同的是步骤2中加入丙酮水溶液后,搅拌并离心(10000rpm)。It is basically the same as Example 1, except that after adding acetone aqueous solution in step 2, it is stirred and centrifuged (10000rpm).
实施例七Embodiment seven
与实施例1基本相同,所不同的是步骤2中萃取用溶剂为乙酸丁酯。It is basically the same as Example 1, except that the extraction solvent in step 2 is butyl acetate.
实施例八Embodiment Eight
与实施例1基本相同,所不同的是步骤3中冷冻干燥改为50℃真空干燥10h。It is basically the same as in Example 1, except that the freeze-drying in step 3 is changed to vacuum drying at 50° C. for 10 h.
实施例九Embodiment nine
与实施例1基本相同,所不同的是步骤2中所用蛋白质溶液为1%鸡蛋清水溶液。It is basically the same as Example 1, except that the protein solution used in step 2 is 1% egg white aqueous solution.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710070553A CN101130498B (en) | 2007-08-24 | 2007-08-24 | Method for extracting and purifying salvianolic acid A |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710070553A CN101130498B (en) | 2007-08-24 | 2007-08-24 | Method for extracting and purifying salvianolic acid A |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101130498A CN101130498A (en) | 2008-02-27 |
CN101130498B true CN101130498B (en) | 2012-08-29 |
Family
ID=39127929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710070553A Expired - Fee Related CN101130498B (en) | 2007-08-24 | 2007-08-24 | Method for extracting and purifying salvianolic acid A |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101130498B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101353306B (en) * | 2008-09-05 | 2011-05-18 | 浙江大学 | Refining method of salvianolic acid A |
CN102212001B (en) * | 2010-04-06 | 2013-11-06 | 山东靶点药物研究有限公司 | Compound salvianolic acid F methyl ester and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
CN100999470A (en) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | Salvia minium phenolic acid A and process of preparing preparation and use |
-
2007
- 2007-08-24 CN CN200710070553A patent/CN101130498B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
CN100999470A (en) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | Salvia minium phenolic acid A and process of preparing preparation and use |
Also Published As
Publication number | Publication date |
---|---|
CN101130498A (en) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109942380A (en) | A kind of method that utilizes high-speed countercurrent chromatographic separation and purification to prepare cannabidiol | |
CN105131062B (en) | A kind of preparation method of Baical Skullcap root P.E | |
CN104892687B (en) | The method that high speed adverse current chromatogram isolates and purifies monomeric compound in Chinese mahonia leaf | |
CN103585311B (en) | A kind of preparation method of Spiraea alpina extract | |
CN112870236A (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
CN101050241A (en) | Method for preparing MDG-1 polysaccharide of lilyturf root | |
CN101348474A (en) | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem | |
CN101538296B (en) | Active components of fern fern and its extraction method and application | |
CN101234147B (en) | Method of preparing total flavones of tropaeolum for injections | |
CN102229638A (en) | Method for extracting oleanolic acid from chaenomeles fruit and preparing oleanolic acid standard | |
CN101130498B (en) | Method for extracting and purifying salvianolic acid A | |
CN105106252A (en) | Method for extracting and separating flavonoid compounds from hypericum japonicum | |
CN103059008B (en) | Method for simultaneously preparing puerarin and daidzein | |
CN101696381B (en) | Novel process for preparing highland barley flavone extract and application thereof in health wine | |
CN101199565B (en) | Active parts of Panax notoginseng flower buds and preparation method thereof | |
CN103585208B (en) | Preparation method of high-quality andrographolide component | |
CN101618052A (en) | Process for extracting total flavonoids from hippophae leaves | |
CN105017201B (en) | A kind of preparation method of pure natural Ligustrum quihoui fruit anthocyanidin | |
CN103819518A (en) | Preparation method for standardized extracts of eucommia ulmoides pinoresinol diglucoside | |
CN103585226B (en) | A kind of preparation method of Herba Elephantopi Mollis extract and application thereof | |
CN102432419A (en) | Method for extracting and separating beta-elemene from Eupatorium adenophorum | |
CN102887925B (en) | The method of ponticin is extracted from Rheum hotaoense C. Y. Cheng et C. T. Kao | |
CN101721449B (en) | Method for preparing lindley eupatorium herb general flavone by using attapulgite adsorption method | |
CN1686258A (en) | Thesium Chinese total flavone preparation method | |
CN105906687A (en) | Method for separating and purifying various tanshinone monomer components from root of red-rooted salvia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 Termination date: 20150824 |
|
EXPY | Termination of patent right or utility model |